Drug Trial Radar · NCT00502307
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
272
Actual
Start
Oct 2007
Primary completion
Aug 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor.
Conditions
- Carcinoma, Renal Cell
Interventions
Tivozanib (AV-951)Drug
solid oral dosage form taken daily for three weeks per one month cycle
Placebo comparatorDrug
solid oral capsule containing excipients dosed daily for three weeks per month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs)Time frame: 28 weeks after study entry
- Objective Response [Complete Response (CR) + Partial Response (PR)] Rate at 16 Week Open-Label Period (All Treated Population)Time frame: 16 weeks after study entry
- Percentage of Randomly Assigned Subjects Remaining Progression Free at 12 Weeks Following Random Assignment to Tivozanib (AV-951) or PlaceboTime frame: 28 weeks after study entry
Locations
26 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Kolkata, India
Site not named
Mumbai, India
Site not named
New Delhi, India
Site not named
Pune, India
Site not named
Vellore, Tamil Nadu, India
Site not named
Astrakhan, Russia
Site not named
Kazan', Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Obninsk, Russia
Site not named
Pyatigorsk, Russia
Site not named
Rostove-on-Don, Russia
Site not named
Saint Petersburg, Russia
Site not named
Sochi, Russia
Site not named
Tomsk, Russia
Site not named
Ufa, Russia
Site not named
Velikiy Novgorod, Russia
Site not named
Yoshkar-Ola, Russia
Site not named
Cherkassy, Ukraine
Site not named
Dnipro, Ukraine
Site not named
Donetsk, Ukraine
Site not named
Kharkiv, Ukraine
Site not named
Lviv, Ukraine
Site not named
Uzhhorod, Ukraine
Site not named
Zaporizzhya, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.